DZ Bank confirms buy recommendation for Pfizer - price target of $32

DZ Bank confirms buy recommendation for Pfizer - price target of $32

DZ Bank left its rating on Pfizer unchanged at “Buy” with a fair value of $32 following the release of figures. According to analyst Elmar Kraus, the pharmaceutical company presented a positive earnings outlook for the first quarter, which contributes to the positive assessment. Kraus highlights that Covid-19-related products Comirnaty and Paxlovid are losing importance, while the rest of the portfolio is experiencing double-digit growth.

This optimistic outlook is based on analysis by Kraus, who sees Pfizer's development as promising. Despite the declining influence of Covid products, Kraus is confident that the company is on a stable growth path with other products. This forecast supports DZ Bank's decision to continue to recommend Pfizer as a purchase.

The updated assessment for Pfizer comes at a time when the pharmaceutical industry continues to be in strong focus. With the ongoing evolution of the healthcare sector and the importance of innovation to the company's future, Pfizer remains an interesting stock for investors. Confirmation of the fair value of $32 underscores DZ Bank's confidence in Pfizer's long-term performance.